Lim Do Hoon
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Brain Tumor Res Treat. 2023 Jan;11(1):22-27. doi: 10.14791/btrt.2022.0033.
During the last three decades, the management of medulloblastoma (MBL) has made enormous progress with a multidisciplinary approach, incorporating surgery, radiotherapy (RT), and chemotherapy. Despite this improvement, 20%-30% of patients with MBL remain at risk of disease recurrence, with its relapse being possibly fatal. To date, the salvage treatment for relapse remains challenging, and various approaches have been suggested for the retreatment. In this review, I have described the characteristics of patients with relapsed MBL, patterns of relapse and the most commonly prescribed treatment. Further, I have reviewed the studies on re-irradiation and its associated issues to conclusively suggest the RT recommendations for patients with relapsed MBL.
在过去三十年中，髓母细胞瘤（MBL）的治疗通过多学科方法取得了巨大进展，该方法包括手术、放射治疗（RT）和化疗。尽管有了这种改善，但20%-30%的MBL患者仍有疾病复发的风险，其复发可能是致命的。迄今为止，复发后的挽救治疗仍然具有挑战性，并且已经提出了各种再治疗方法。在这篇综述中，我描述了复发MBL患者的特征、复发模式以及最常用的规定治疗方法。此外，我回顾了关于再照射及其相关问题的研究，以便最终提出复发MBL患者的放疗建议。
